The Midlands Therapeutics Review and Advisory Committee (MTRAC) has published reviews of the four drugs available for Alzheimer's disease.
The reviews of donepezil, galantamine, memantine and rivastigmine place all of the drugs as having a lower place in therapy with relatively weak evidence supporting use. Donepezil, galantamine and rivastigmine are suitable for prescribing in primary care provided that there is continued monitoring in secondary care or through shared care arrangements and treatment is stopped when appropriate as specified in the existing NICE Guidance. Memantine is classified as unsuitable for use in primary care.
Action: Clinicians will find these reviews contain a useful summary of the trial data for each drug. Throughout the trial data the reviews reveal small overall benefits, inconsistent results and use of subjective measures.
|« ADR reporting campaign launched||Glucosamine ineffective for hip OA »|